Jurilab

Jurilab was a Finnish biotechnology company specializing in the discovery of genes and biomarkers associated with common complex diseases. The company leveraged the unique genetic homogeneity of the Eastern Finnish population to identify genetic variations linked to conditions such as type 2 diabetes, asthma, and cardiovascular disease. Their research platform integrated extensive clinical data with high-throughput genomic analysis to provide targets for drug discovery and personalized medicine. Jurilab's primary goal was to develop pharmacogenomic products that could predict patient response to specific therapies. In 2005, the company was acquired by Clinical Data, Inc. for approximately $15.5 million. This acquisition allowed Clinical Data to incorporate Jurilab's genetic discovery capabilities into its broader molecular diagnostics portfolio.